CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 44 enrolled
Drug / intervention
dorzolamide/timolol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01175902
NCT01175902N/ACompleted
CompareCT.gov

To Prove the Non-inferiority of Cosopt Compared to Xalatan in the Aspects of Intraocular Pressure and Ocular Perfusion Pressure in Subjects With Normal Tension Glaucoma

The Catholic University of Korea·interventional·Posted Aug 5, 2010·Updated Jan 8, 2015

In Brief

A clinical study evaluating dorzolamide/timolol and latanoprost for Normal Tension Glaucoma. Completed, enrolled 44 participants across 1 site.

Detailed Summary

To prove the non-inferiority of the fixed timolol-dorzolamide combination (Cosopt) compared to 0.005% latanoprost (Xalatan) in the aspects of intraocular pressure (IOP) and ocular perfusion pressure (OPP) in subjects with normal tension glaucoma (NTG) Clinical hypotheses. Primary hypothesis * Cosopt group is non-inferior to Xalatan group in diurnal IOP reduction. Secondary hypothesis * Cosopt group is non-inferior to Xalatan group in diurnal diastolic and systolic OPP.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNormal Tension Glaucoma
CountriesSouth Korea
CollaboratorsSeoul St. Mary's Hospital

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 5, 2010
Enrollment StartMar 1, 2011
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 15.9 years ago

Interventions

dorzolamide/timololdrug

dorzolamide/timolol fixed combination eyedrop, 2 times a day

latanoprostdrug

compare with dorzolamide/timolol fixed combination eyedrop one time a day